PRINCETON, N.J., May 3, 2022 — Certara, Inc., a global leader in biosimulation, today announced that the Company’s Simcyp COVID-19 Vaccine Model has been awarded a 2022 Bronze Edison Award in the Therapeutic Impact category.
The Simcyp COVID-19 Vaccine Model, which is incorporated in Certara’s Vaccine Simulator, uses biosimulation and computer-generated, virtual populations to facilitate global vaccine decision-making. It addresses important COVID-19 vaccine questions such as what are the optimal dose and timing, are there differences in immune response with age and ethnicity, and what is the expected duration of antibody response.
“We are honored to be recognized for our contribution to fighting the pandemic with the COVID-19 vaccine model,” said Piet van der Graaf, senior vice president of Quantitative Systems Pharmacology at Certara. “Our dedicated team has worked tirelessly with our pharma partners to develop and refine the Vaccine Simulator to predict responses to vaccines and inform critical decisions that help to improve patient outcomes, including in the elderly and pediatric populations.”
Winning an Edison Award is one of the highest accolades a company can receive for the successful launch of a “game-changing” new product or service. The 2022 Edison Award Winners come from many nations around the world and represent a diverse population of people, products, industries and target communities.
“The 2022 Edison Award winners are not only innovators, but also leaders in their field and community. We award this honor for the technological advances and the impact on industry. We know that their innovations will have long lasting effects on the world,” said Frank Bonafilia, executive director of the Edison Awards.
The complete list of Edison winners is showcased at www.edisonawards.com.
Learn more about Certara’s biosimulation technology at https://www.certara.com/software/quantitative-systems-pharmacology/.
About Certara
Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.
About the Edison Awards
The Edison Awards™ is an annual honor designed to recognize excellence in new product and service development, marketing, human-centered design and innovation. Started in 1987 and named after Thomas Edison, the vision of the Edison Awards is guided by his legacy, vision and the Menlo Park team who successfully brought an unprecedented number of innovations to the market. Edison Award recipients represent “game changing” products, services and excellence in leadership and innovation. For more information about the Edison Awards, complete program and a list of winners, visit www.edisonawards.com.